Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Anticancer Drugs. 2011 Feb;22(2):115-27. doi: 10.1097/CAD.0b013e328341185b.

Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report.

Author information

  • 1Department of Chemistry, University of Toronto, Mississauga, Canada.

Abstract

Aberrantly activated signal transducer and activator of transcription 3 (Stat3) protein plays a master regulatory role in the progression and survival of human cancers through the upregulation of target protooncogenes. Numerous human cancers, including breast, ovarian, prostate, leukemia, lymphoma, multiple myeloma, and brain cancers have been shown to harbor constitutively active Stat3 protein resulting in the expression of protooncogenes. The transcriptionally active Stat3-Stat3 protein homodimer has been extensively targeted as a means to suppress the aberrant Stat3 function in human cancer. This review will outline the recent progress made toward identifying drug-like compounds capable of effectively inhibiting aberrant Stat3 signaling through the disruption of Stat3 protein-protein interactions.

PMID:
21063201
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Write to the Help Desk